Karyopharm Therapeutics KPTI Cash Flow Statement (2012-2026)

NASDAQ KPTI
$1.69 -0.03 (-1.74%)
As of: Sep 9, 2026 · 3:59 PM EDT
Reported Financials

Karyopharm Therapeutics Quarterly Cash Flow Statement

Periods 54 quarters
Latest Jun 2026

Karyopharm Therapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 54 quarters of results from Dec 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating Activities
Net Income
-53.58M-51.81M38.69M-41.40M-49.06M-36.32M-39.43M-34.13M-32.63M-34.51M-42.08M-37.36M23.79M-32.07M-30.86M-23.46M-37.25M-33.13M-61.00M-67.02M
Share-based CompensationStock Comp.
8.13M7.42M6.87M7.34M15.09M6.80M6.17M5.39M6.06M5.08M5.18M5.41M5.41M4.18M3.86M3.78M3.78M2.80M3.90M1.93M
Asset Writedowns and ImpairmentWritedown
0.10M0.20M
Cash from OperationsCash from Ops.
-55.75M-23.95M25.48M-59.20M-35.14M-28.37M-26.84M-18.91M-25.70M-29.53M-18.59M-43.73M-38.50M-19.45M-25.81M-38.98M-18.70M-5.86M-11.83M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.48M-0.27M-0.14M-0.04M0.12M0.29M0.46M1.13M1.01M0.94M1.02M0.91M0.67M0.53M0.39M0.24M0.12M0.04M0.01M
Amortization of Deferred ChargesAmort. Deferred Charges
0.20M0.20M0.20M0.20M0.20M0.20M0.21M0.20M0.19M0.20M0.22M0.21M1.40M2.41M2.36M2.57M2.72M2.81M2.44M
Depreciation & Amortization (CF)Dep. & Amort.
Change in Working Capital
Change in ReceivablesChange Receivables
0.04M0.86M3.75M2.50M-1.51M3.97M0.14M-11.89M-2.92M5.64M-10.96M4.12M6.91M-6.22M-1.01M4.48M-2.31M-1.05M-5.70M
Change in InventoryChange Inventory
0.95M-0.12M0.08M-0.23M-0.40M0.78M-0.03M-0.40M-0.15M-0.57M-0.06M-0.27M0.71M1.20M0.07M0.03M0.22M-1.03M0.07M
Change in Account PayablesChange Payables
-0.73M-1.43M0.72M1.84M-1.75M-0.88M1.96M6.27M-6.76M-1.34M2.18M1.91M-2.23M2.99M-0.68M0.77M-3.27M2.79M-1.39M
Change in Accured ExpensesChange Accured Exp.
-3.24M12.09M3.68M-9.39M-2.18M-0.05M2.08M-9.41M5.34M3.30M4.78M-4.86M0.06M2.55M6.45M-0.41M8.58M9.45M1.44M
Other Working Capital ChangesOther WC Changes
Investing Activities
Capital ExpendituresCapex
0.01M0.21M0.08M0.04M0.20M-0.05M
Change in Acquisitions & DivestmentsChange Acquisitions
55.43M37.93M30.48M21.58M26.88M41.61M31.80M27.94M57.36M38.38M43.40M53.74M56.16M28.28M16.25M15.29M18.29M4.80M5.00M
Cash from Investing ActivitiesCash from Investing
46.46M21.43M30.77M-14.04M-36.60M11.67M-65.30M-32.39M21.17M-7.68M26.84M21.94M51.26M7.47M14.80M15.29M18.29M4.80M5.00M
Financing Activities
Other financing activitiesOther financing
2.06M0.02M0.90M1.47M1.33M0.01M1.16M0.86M0.26M0.68M0.41M
Cash from Financing ActivitiesCash from Financing
62.06M0.02M0.90M30.78M1.31M5.80M155.84M0.86M0.26M0.68M29.69M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
3.58M722.90M3.58M2.67M0.27M
Net Equity Issued and RepurchasedNet Equity Issued
Additional items
Exchange Rate EffectFX Effect
-0.06M0.24M-0.14M-0.09M-0.45M-0.07M0.13M-0.04M-0.03M-0.05M0.09M-0.02M-0.01M0.04M-0.02M0.01M0.01M0.00M0.01M
Change in Cash
52.71M-2.27M57.01M-42.54M-70.88M-10.97M63.83M-51.34M-3.69M-37.27M8.61M-21.80M53.72M-11.94M-10.35M-23.69M-0.05M-1.05M22.87M
Free Cash FlowFCF
-55.75M-23.96M25.27M-59.28M-35.14M-28.41M-26.84M-18.91M-25.70M-29.53M-18.59M-43.92M-38.50M-19.45M-25.76M-38.98M-18.70M-5.86M-11.83M
Net Cash FlowNCF
52.77M-2.51M57.14M-42.45M-70.43M-10.90M63.70M-51.30M-3.67M-37.22M8.52M-21.79M12.76M-11.98M-10.33M-23.70M-0.41M-1.05M22.86M